Maryland, D.C., and Virginia — one of the largest life science corridors in the U.S.
Explore →
Philadelphia, South Jersey, and Delaware — a powerhouse of pharma and biotech innovation.
Explore →
North Carolina's Research Triangle — a growing hub for biotech and life sciences.
Explore →
From CMC strategy and analytics to CDMO partnerships and AI-enabled operations, life sciences ecosystem gathered at Propel Labs to discuss the growing pressure to execute with speed and precision. The biotech industry is entering a new phase where breakthrough science alone is no longer enough to attract capital, reach the clinic, or survive long enough […]
Read More →A fireside chat with AstraZeneca’s Dafni Kika at ISPE MAST Showcase made the case that decarbonization, AI, and people-centered leadership are converging into one operating discipline for pharma. When Dafni Bika, Ph.D., started out as a materials scientist and chemical engineer, nobody in her labs said “sustainability.” They called it value engineering — wringing every […]
MANASSAS, Va. —Jeeva Clinical Trials announced the acquisition of Clintelligence AI, an AI-powered protocol intelligence platform designed to improve trial planning, accelerate patient recruitment, and reduce clinical development risk. The acquisition expands Jeeva’s growing AI-ready clinical research infrastructure and strengthens its position as a next-generation platform for decentralized and hybrid clinical trials. The integration of […]
ROCKVILLE, Md. — May 13, 2026 — Bora Pharmaceuticals, a Taiwan-based contract development and manufacturing organization (CDMO), has entered into an agreement to acquire MacroGenics’ biologics manufacturing facility and related warehouse operations in Rockville, Maryland, for $122.5 million upfront, with the potential for an additional $5 million tied to future operational milestones. The transaction expands […]
When Gilead Sciences announced its $7.8 billion acquisition of Arcellx earlier this year, the deal was largely framed as a strategic win in the escalating race to dominate next-generation CAR-T therapies. The acquisition gives Gilead full control of anito-cel, a late-stage multiple myeloma therapy viewed by many as one of the most promising challengers in […]
In life sciences, the conversation around AI has moved quickly from if to how. But beneath that momentum lies a more fundamental question: are organizations actually ready to use it? That gap—between interest and readiness—is becoming one of the defining challenges for the industry. At the upcoming AAPS National Biotechnology Conference, that tension will be […]
For much of modern drug development, the question hasn’t just been can we target the biology—it’s been can we prove it early enough to matter. That tension is becoming increasingly visible as therapies grow more precise and biology more complex. At this year’s AAPS National Biotechnology Conference, that challenge is moving to the forefront, with […]
Aldevron, a Danaher company and global leader in the production of DNA, RNA, and proteins for genomic medicine, and Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodal biosafety testing provider, announced the renewal of their lentiviral plasmid licensing agreement designed to expand access to scalable plasmid solutions […]
In conversation with Heffron’s Matt McGrath on the people and projects enabling innovation to scale In life sciences, the spotlight often falls on discovery—on the science, the therapeutics, the breakthroughs. But behind every lab, cleanroom, and manufacturing suite is a different kind of expertise: the people responsible for building the environments where innovation can actually […]
When large pharmaceutical service businesses change hands, the headline is usually about the deal size. But the formation of Rose BioSolutions following GI Partners’ acquisition of Charles River Laboratories’ CDMO and Cell Solutions businesses signals something larger: infrastructure for advanced therapies is being repositioned as a long-term strategic asset rather than a volatile services add-on. […]
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
